Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

BBenitec Biopharma Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
B

Benitec Biopharma Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
    Sep 14, 2026Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
    May 14, 2026Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
    Apr 28, 2026Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
    Mar 10, 2026Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
    Mar 9, 2026Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
    Feb 23, 2026Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
    Feb 12, 2026Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
    Jan 11, 2026Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
    Nov 14, 2025Benitec Biopharma Inc. (BNTC) Press Releases
  • Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
    Nov 6, 2025Benitec Biopharma Inc. (BNTC) Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$8.99Close · Oct 7, 2026